Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dacomitinib - Pfizer

Drug Profile

Dacomitinib - Pfizer

Alternative Names: Dacomitinib; PF-00299804; PF-299; PF-299804; PF-804; VIZIMPRO

Latest Information Update: 11 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Developer Fondazione IRCCS Istituto Nazionale dei Tumori; Memorial Sloan-Kettering Cancer Center; Netherlands Cancer Institute; Pfizer; Seoul National University Hospital; SFJ Pharmaceuticals; University Health Network; University of California, San Diego
  • Class Amides; Aniline compounds; Antineoplastics; Piperidines; Quinazolinones; Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists; ERBB 2 receptor antagonists; ERBB 4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Non-small cell lung cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Non-small cell lung cancer
  • Phase II Squamous cell cancer
  • Discontinued Brain metastases; Gastric cancer; Glioblastoma; Head and neck cancer; Orofacial cancer; Solid tumours

Most Recent Events

  • 22 Jul 2019 National Cancer Centre and Pfizer plans a phase II trial for Non-small cell lung cancer (First-line therapy, Late-stage disease, Metastatic disease, Newly diagnosed, Recurrent) in Hong Kong, Malaysia, Singapore, South Korea Thailand and Taiwan in August 2019 (PO) (NCT04027647)
  • 30 May 2019 Pfizer completes a phase II trial for Non-small cell lung cancer in Japan (NCT02382796)
  • 03 Apr 2019 Registered for Non-small cell lung cancer (First-line therapy, Late-stage disease, Metastatic disease, Monotherapy, Recurrent) in European Union, Iceland, Norway, and Liechtenstein (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top